Breast Biopsy Market to Experience Significant Growth by 2035
Breast biopsy market is driven by the increasing prevalence of breast cancer, rising awareness regarding early cancer detection, and growing adoption of minimally invasive diagnostic procedures across healthcare facilities. Advancements in imaging technologies such as MRI-guided, ultrasound-guided, and stereotactic biopsy systems, along with increasing demand for accurate and rapid diagnostic solutions, are further supporting market growth. In addition, the expansion of healthcare infrastructure, rising government initiatives for breast cancer screening programs, and continuous product innovations in biopsy needles and guidance systems are accelerating the adoption of breast biopsy procedures globally.
Browse the full report description of “Breast Biopsy Market Size, Share & Trends Analysis by Type (Fine Needle Biopsy, Core Needle Biopsy, Surgical Biopsy, and Others (Lymph Node and Vacuum-Assisted Biopsy)), By Product (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kit, and Other), By Guided Technology (MRI-Guided Biopsy, Ultrasound-Guided Biopsy, Mammography Guided Stereotactic Biopsy, CT-Guided Biopsy and Other), By End-User (Hospitals, Diagnostic Centre, and Research Institute), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/breast-biopsy-market
Mammotome launched the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System in 2026
Mammotome, a Danaher company, announced the launch of the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System in February 2026. The system is recognized as the industry’s first in-room MR vacuum-assisted breast biopsy platform designed to be positioned directly inside the MRI scanner room beside the patient during procedures. The innovation improves clinician coordination, enhances workflow communication, and supports more efficient MRI-guided breast biopsy procedures by allowing direct device accessibility within the scanning environment. The launch also reflects the growing adoption of advanced image-guided biopsy technologies focused on improving procedural accuracy, patient comfort, and operational efficiency in breast cancer diagnostics.
BD received FDA clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System in 2026
BD announced in January 2026 that the U.S. Food and Drug Administration granted 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System. The advanced multi-modality breast biopsy platform was developed to provide clinicians with enhanced flexibility across breast imaging technologies, including ultrasound, stereotactic, and MRI-guided procedures. The system supports efficient tissue sampling and breast lesion removal while improving workflow capabilities for healthcare providers. The FDA clearance strengthens BD’s breast intervention portfolio and highlights the increasing focus on technologically advanced biopsy systems designed to improve breast cancer diagnosis and minimally invasive treatment procedures.
Vacuum-assisted breast biopsy systems segment is expected to account for a major market share in 2026
Vacuum-assisted breast biopsy systems are expected to hold a major market share in 2026, primarily due to their high diagnostic accuracy, minimally invasive capabilities, and increasing adoption across breast cancer screening and diagnostic procedures. These systems are widely used for collecting larger and higher-quality tissue samples with fewer needle insertions, improving procedural efficiency and patient comfort compared to conventional biopsy techniques. Rising global breast cancer incidence, increasing awareness regarding early-stage cancer detection, and growing demand for image-guided minimally invasive procedures are major factors driving segment growth. In addition, technological advancements in MRI-guided, stereotactic, and ultrasound-guided biopsy systems are further accelerating market adoption across hospitals, specialty clinics, and diagnostic imaging centers worldwide.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404